0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$73.00
This product is available by prescription only
This product does not require a prescription
Out Of Stock
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
Vasoactive intestinal peptide is a 28-amino acid neuropeptide that binds with high affinity to VPAC1 and VPAC2 G-protein-coupled receptors, both of which are expressed across immune, epithelial, smooth muscle, and neuronal cell populations. This broad receptor distribution makes VIP a relevant model compound for studying neuropeptide-receptor interaction dynamics across multiple tissue system models simultaneously. Binding at VPAC receptors initiates cAMP-dependent intracellular signaling cascades, enabling researchers to examine downstream PKA pathway activity and transcription factor modulation in controlled cell-based assays.
VIP is studied for its modulatory effects on pro-inflammatory cytokine expression — including TNF-α, IL-6, and IL-12 — and its association with elevated anti-inflammatory cytokine marker activity such as IL-10 in preclinical immune cell models. Researchers use VIP to examine how VPAC receptor activation influences cytokine transcription factor activity, NF-κB pathway signaling, and MAPK cascade dynamics in macrophage, dendritic cell, and T-lymphocyte experimental systems. These molecular endpoints support detailed mechanistic characterization of neuropeptide-mediated immune signaling pathway behavior.
VIP’s expression across enteric nervous system, respiratory mucosal tissue, and central nervous system cell populations makes it a relevant research compound for studying neuroimmune signaling dynamics at tissue-system interfaces. Laboratories examining gut-brain axis neuropeptide signaling, airway neuroimmune pathway activity, or lymphoid tissue receptor expression use VIP as a structurally defined reference compound for multi-system receptor interaction studies.
VIP 6mg is manufactured by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party analysis. COA documentation accompanies each vial, confirming the complete 28-amino acid sequence identity, purity grade, and batch consistency. This level of characterization ensures reproducible material for advanced neuropeptide receptor signaling and neuroimmune pathway research.
VIP 6mg is suited for research teams investigating VPAC receptor binding dynamics, neuropeptide-mediated cytokine pathway modulation, and neuroimmune signaling interactions in controlled laboratory models. Laboratories examining VIP receptor occupancy across immune cell subtypes, gut mucosal signaling marker expression, or airway-associated neuroimmune pathway activity will find this compound relevant to mechanistic study designs. Research programs investigating gut-brain axis neuropeptide signaling, T-regulatory cell pathway activity, or bronchial smooth muscle receptor dynamics benefit from this compound’s well-characterized 28-amino acid structure. Produced by Elivena in USA GMP-certified facilities, each vial is COA-verified for sequence identity and purity.
VIP supports in-vitro investigation of VPAC1 and VPAC2 receptor binding kinetics, ligand affinity characterization, and receptor subtype selectivity in cell line and primary culture models. Researchers examining cAMP second messenger activity, PKA phosphorylation dynamics, and downstream transcriptional marker expression following VPAC receptor activation use VIP as a primary reference ligand for receptor pharmacology study designs.
Laboratories studying neuropeptide-mediated modulation of cytokine network dynamics use VIP to examine changes in pro- and anti-inflammatory cytokine marker expression in immune cell experimental models. Research designs quantify NF-κB pathway activation status, cytokine transcription factor binding activity, and secreted protein marker levels following VPAC receptor stimulation — contributing to mechanistic understanding of neuropeptide involvement in immune signaling pathway regulation.
VIP is studied in gastrointestinal mucosal model systems for its interaction with enteric nervous system signaling pathways and epithelial barrier marker expression. Researchers examining intestinal mucosal receptor distribution, enteric neurotransmission dynamics, and paracellular permeability marker activity utilize VIP to characterize neuropeptide contributions to gut mucosal signaling at a molecular level — without referencing clinical or physiological outcome endpoints.
VIP’s activity at VPAC receptors expressed in bronchial smooth muscle and airway epithelial cell populations makes it relevant for studies examining neuropeptide-mediated smooth muscle receptor signaling, cAMP-dependent relaxation pathway marker activity, and airway immune cell cytokine endpoint quantification in controlled preclinical respiratory models.
VIP 6mg with sterile bacteriostatic water or sterile saline using standard sterile laboratory technique. VIP should be used promptly following reconstitution due to its susceptibility to enzymatic degradation under non-optimized storage conditions. Reconstitution volume should be determined based on the target experimental concentration specified by the study design. Use calibrated laboratory equipment for all preparation and handling steps.
Store lyophilized peptide at 2–8°C or -20°C for long-term stability, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C and use within the shortest timeframe consistent with the laboratory protocol to preserve neuropeptide integrity. Lyophilized material does not require cold-chain shipping but should be refrigerated upon receipt. Each Elivena vial is supplied with COA documentation and handling guidance.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic nonapeptide supplied in 5mg format for controlled in vitro laboratory investigation.
Research-grade cathelicidin-derived peptide formulated for experimental immune-related research in controlled laboratory environments.
Research-grade synthetic pentadecapeptide designed for controlled laboratory peptide studies and institutional research programs.
Research-grade synthetic dual-agonist peptide formulated in higher-quantity 15mg format for extended dual-receptor pathway studies and institutional peptide research in controlled laboratory environments.
Research-grade dual-peptide formulation combining two synthetic peptides for streamlined laboratory peptide research protocols.
